Thanks to a new, national partnership, Breakthrough T1D and Tandem Diabetes Care are teaming up to help drive awareness and education on topics related to technology innovation, diabetes management and healthcare for people with diabetes.
“Together, we will show how innovations in type 1 diabetes (T1D) management and care will continue to minimize the intrusions of T1D on day-to-day life and provide better health outcomes for people living with the disease,” said Joe Watterson, Breakthrough T1D Vice President of Corporate Development.
The partnership will utilize Breakthrough T1D’s community facing platforms—including local chapter events, digital channels and education programs—to highlight the benefits of devices such as insulin pumps, continuous glucose monitors, and novel treatment approaches like hybrid closed loop therapy.
People living with T1D have a variety of needs that span from reducing the daily burden of disease management to finding a trusted technology partner who can deliver solutions that work reliably, provide clinical benefits and improve their overall quality of life.
The Breakthrough T1D and Tandem partnership aims to actively support the growing needs of the T1D community and help address the gap in diabetes education on these topics through regional and local activities, including select Community Summits and Breakthrough T1D Walk events.
“Education is the foundation for improved quality of life and clinical outcomes for people with type 1 diabetes, and we are proud to partner with Breakthrough T1D in furthering our shared mission to support the diabetes community,” said Brian Hansen, Executive Vice President and Chief Commercial Officer at Tandem Diabetes Care.
Recently Expand Choice for Prospective Tandem Users
Thanks to a concerted effort that included mobilizing Breakthrough T1D’s grassroots network of T1D champions across the nation, UnitedHealthcare (UHC) recently announced it would cover the t:slim X2 insulin pump from Tandem Diabetes in network, starting July 1, 2020.
This came on the heels of FDA clearance of an expanded pediatric indication for the Tandem t:slim X2™ insulin pump with Control-IQ™ technology in children ages six and older. Initially, the device was only authorized for use in people 14 and older.
